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Pharmaceutical analysis plays an indispensable role in the development of novel safer, cheaper 
and more effective drugs and chaperones them from their first synthesis throughout their 
existence. To date, the method most commonly used in pharmaceutical analysis is liquid 
chromatography (LC) with various detection modalities. Separation via LC enables analysis of 
very complex mixtures such as biological samples or samples from stability studies. The soaring 
interest in LC hyphenated with mass spectrometry (MS) in pharmaceutical analysis is partly 
due to its increasing affordability and mainly due to its ability to separate the molecules of the 
analyte according to their mass-to-charge ratio (m/z). The additional dimension of separation 
grants it a superior selectivity. In addition, MS provides priceless information on the structure 
of the analyte – be it the m/z or fragmentation spectra. 
In its theoretical part, this dissertation deals with basic description of liquid chromatography, 
mass spectrometry, validation of analytical and bioanalytical methods, stability assessment, 
pharmacokintetics and the analytes of interest. The second part, the commentary on the 
published work, consists of two units: 1) bioanalytical assessment of pharmacokinetics of 
thiosemicarbazones – novel anticancer agents, freshly under clinical trials and 2) analytical 
assessment of stability of carfilzomib – a new proteasome-inhibiting anticancer drug. 
In the first unit, I discuss our bioanalytical approaches for assessment of metabolism and 
pharmacokinetics of three generations of promising anticancer drugs both in vitro and in vivo, 
especially aiming at their development and application. Using the developed method we found 
that: 1) the studied – structurally close – thiosemicarbazones differ in pharmacokinetics and 
metabolism both qualitatively and quantitatively; 2) the bulky substitution on the terminal 
nitrogen protects the thiosemicarbazones from metabolism and the consequential loss of 
pharmacological effect; 3) the toxic concentrations of the metabolites are rather unlikely to 
occur in vivo under standard dosing and 4) the different pharmacokinetic and toxicity profiles 
of these three generations of anticancer drugs are not linked. 
In the second unit of the experimental part, I comment on the first published stability 
indicating method for carfilzomib – a new anticancer drug – that we applied to stability 
assessment of this drug and to identification of possible degradation products. This method 
might be further used in development of potential future generic, in potential experimental 
development of alternative formulations or as a starting point for new methods for 
determination of carfilzomib. 
